Clinical trial
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very…
NCT00215540 · Windtree Therapeutics, Industry · Terminated
Key facts
| NCT number | NCT00215540 |
|---|---|
| Title | SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants. |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Efficacy of SURFAXIN® (Lucinactant), in Very Low Birth Weight (VLBW) Infants at Risk for Developing Bronchopulmonary Dysplasia |
| Lead sponsor | Windtree Therapeutics, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia |
| Intervention type | Drug |
| Interventions | Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo |
| Enrollment | 136 |
| Start date | Feb 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Sep 22, 2005 |
| Last update posted | Jun 13, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: